OTCMKTS:ARNI Arno Therapeutics (ARNI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Arno Therapeutics Stock (OTCMKTS:ARNI) Get Arno Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume8,820 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Arno Therapeutics, Inc. (OTCMKTS:ARNI) is a development‐stage biopharmaceutical company focused on the research and development of targeted therapeutics for oncology indications and rare genetic disorders. The company’s mission is to apply innovative biologic and protein engineering platforms to create therapies that address significant unmet medical needs in cancer and inherited metabolic conditions. Arno’s pipeline centers on antibody‐based drug conjugates and recombinant fusion proteins designed to selectively target tumor cells or restore deficient enzyme activity in rare diseases. Although its programs remain in preclinical and early development stages, the company has secured intellectual property rights and in‐licensed technologies to advance multiple candidates toward Investigational New Drug (IND) filings. To bolster its research efforts, Arno Therapeutics has entered into collaboration and licensing agreements with academic institutions and specialized biotechnology firms. These partnerships grant access to novel targeting platforms, enhance preclinical data generation and support scale‐up activities in anticipation of future clinical trials. The company aims to leverage these relationships to accelerate development timelines and de‐risk its lead programs. Headquartered in Delray Beach, Florida, Arno Therapeutics is led by a management team with experience in biopharmaceutical development, clinical operations and regulatory affairs. The company continues to build its organizational capabilities, with the goal of advancing its pipeline and establishing a presence in U.S. and select international markets upon achieving clinical milestones.AI Generated. May Contain Errors. Read More Receive ARNI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARNI Stock News HeadlinesBuffalo moves to dismiss lawsuit over firefighter Jason Arno’s deathOctober 2, 2025 | msn.comBuffalo Fire Department, city file new documents in Arno wrongful death lawsuitOctober 2, 2025 | msn.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.August 18 at 1:00 AM | Awesomely (Ad)ARNI Arno Therapeutics, Inc. - Seeking AlphaJuly 1, 2025 | seekingalpha.comLas Vegas Metro K9 Arno, explosive detection dog, dies post-retirementNovember 13, 2024 | yahoo.comK9 Arno, veteran explosive detector dog, dies at 13November 9, 2024 | msn.comAdrian Aglow ministry welcomes Nancy Jenkins-Arno as guest speaker during Oct. 22 meetingOctober 18, 2024 | news.yahoo.comJason Arno will be honored at this weekend's Fallen Fire Fighter Memorial ServiceSeptember 20, 2024 | msn.comSee More Headlines ARNI Stock Analysis - Frequently Asked Questions How do I buy shares of Arno Therapeutics? Shares of ARNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arno Therapeutics investors own include Ampliphi Biosciences (APHB), Armata Pharmaceuticals (ARMP), Aurora Cannabis (ACB), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS) and Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ARNI CIK1195116 Webwww.arnothera.com Phone(503) 598-6659FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:ARNI) was last updated on 8/18/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredI’m sharing my top day trading secrets for freeA 30-year trading veteran who managed multi-million-dollar hedge funds and wealth for one of the world's riche...The TradingPub | SponsoredTrump’s “BIG MISTAKE” stock is still dirt cheapA U.S. energy producer operating across 3.7 million acres now pumps roughly 143,299 barrels of oil and 467 mil...Monument Traders Alliance | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arno Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.